<DOC>
	<DOC>NCT02001909</DOC>
	<brief_summary>To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects</brief_summary>
	<brief_title>Effect of Neomycin on the Pharmacokinetics of Regorafenib</brief_title>
	<detailed_description />
	<mesh_term>Neomycin</mesh_term>
	<criteria>Inclusion: Healthy male subjects Age: 18 to 45 years (inclusive) at the first screening examination/visit Body mass index (BMI): above/equal 18 and below 30 kg / mÂ² Confirmation of the subject's health insurance coverage prior to the first screening examination/visit Subjects enrolled in this study must use adequate barrier birth control measures prior to, during the course of the study, and 3 months after the last administration of regorafenib. An adequate contraception includes the use of condoms or a vasectomy. In addition, adequate birth control measures for the subject's partner is required, such as a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, or hysterectomy. Exclusion: Known or suspected hypersensitivity to regorafenib and/or neomycin Any illness or medical condition that is unstable or could jeopardize the safety of the subject and his compliance in the study Clinically significant illness within 30 days prior to Day 1, Period 1. Regular use of medicines at the time of screening, including herbal supplements and high dose vitamins Smoking; however, former smokers who have stopped smoking at least 3 months before the first study drug administration may be included Clinically relevant findings in the electrocardiogram (ECG) Clinically relevant findings in the complete physical examination Positive results for hepatitis B virus surface antigen (HBsAg), hepatitis C virus antibodies (antiHCV), human immune deficiency virus antibodies (antiHIV 1+2) at screening. Positive urine drug screening</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Neomycin</keyword>
	<keyword>Cancer</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Safety</keyword>
</DOC>